This site is intended for Healthcare professionals only.

Mylan launches generic Mutamycin injection in US

Mylan launches generic Mutamycin injection in US

Global pharmaceutical company Mylan NV announced the U.S. launch of the oncology drug Mitomycin for Injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial Single Dose Vials, a generic version of the reference listed drug, Bristol Myers Squibb’s Mutamycin®.

The product is used in combination with other cancer medicines in the treatment of stomach and pancreatic cancers.

Mylan is offering Mitomycin for Injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial Single Dose Vials to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).

Mylan’s injectables portfolio is one of the largest and most diversified in the industry, with approximately 80 injectable products in the U.S. across several therapeutic areas. Mylan is also one of the largest suppliers of cancer medicines by volume in the U.S.

U.S. sales for Mitomycin for Injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial Single Dose Vials were approximately $59 million for the 12 months ending Jan. 31, 2018, according to IQVIA.

Currently, Mylan has 206 ANDAs pending FDA approval representing approximately $93.8 billion in annual brand sales, according to IQVIA. Forty-six of these pending ANDAs are potential first-to-file opportunities, representing $42.2 billion in annual brand sales, for the 12 months ending December 31, 2017, according to IQVIA.

According to its indication, Mitomycin Injection is not recommended as a single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy.

Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of mitomycin.

Hemolytic Uremic Syndrome (HUS) a serious complication of chemotherapy, consisting primarily of macroangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure, has been reported in patients receiving systemic mitomycin.

The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs; however, most cases occur at doses ≥ 60 mg of mitomycin. Blood product transfusion may exacerbate the symptoms associated with this syndrome. The incidence of the syndrome has not been defined.

Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.

Spread the love

Source: Press Release
0 comment(s) on Mylan launches generic Mutamycin injection in US

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted